loading page

Construction of a Prognostic Model for Lung Adenocarcinoma Based on from Heat Shock Protein-Related Genes and Immune Analysis
  • +4
  • Wangyan Zhou,
  • Wei Zeng,
  • Dayang Zheng,
  • Xu Yang,
  • Yongcheng Qing,
  • Chunxiang Zhou,
  • Xiang Liu
Wangyan Zhou
The First Affiliated Hospital, Hengyang Medical School, University of South China
Author Profile
Wei Zeng
The Second Affiliated Hospital,Hengyang Medical School, University of South China
Author Profile
Dayang Zheng
The Second Affiliated Hospital,Hengyang Medical School, University of South China
Author Profile
Xu Yang
The Second Affiliated Hospital,Hengyang Medical School, University of South China
Author Profile
Yongcheng Qing
The Second Affiliated Hospital,Hengyang Medical School, University of South China
Author Profile
Chunxiang Zhou
The Second Affiliated Hospital,Hengyang Medical School, University of South China
Author Profile
Xiang Liu
The Second Affiliated Hospital,Hengyang Medical School, University of South China

Corresponding Author:[email protected]

Author Profile

Abstract

Lung adenocarcinoma (LUAD) represents a prevalent form of cancer, with low early diagnosis rates and high mortality rates, posing a global health challenge. Heat shock proteins (HSPs) assume a crucial role within the tumor immune microenvironment (TME) of LUAD. Here, a collection of 97 HSP-related genes (HSPGs) was assembled based on prior literature reports, of which 36 HSPGs were differentially expressed in LUAD. In The Cancer Genome Atlas (TCGA) cohort, we constructed a prognostic model for risk stratification and prognosis prediction by integrating 13 HSPGs. In addition, the prognostic significance and predictive efficacy of the HSP-related riskscore were examined and validated in the Gene Expression Omnibus (GEO) cohort. To facilitate the clinical use of this riskscore, we also established a nomogram scale by verifying its effectiveness through different methods. In light of these outcomes, we concluded a significant correlation between HSP and TME in LUAD, and the riskscore can be a reliable prognostic indicator. Furthermore, this study evaluated the differences in immunophenoscore, TIDE score, and sensitivity to several common chemotherapy drugs among LUAD individuals in different risk groups, which may aid in clinical decision-making for immune therapy and chemotherapy in LUAD individuals.